Skip to main
HLVX
HLVX logo

HilleVax Inc (HLVX) Stock Forecast & Price Target

HilleVax Inc (HLVX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

HilleVax Inc., as a clinical-stage biopharmaceutical company, is advancing its promising vaccine candidate HIL-214, which has demonstrated exceptional immunogenicity, achieving a geometric mean fold rise greater than 18-fold in pan-Ig antibodies and impressive seroresponse rates of 99.0% and 86.9% for norovirus genotypes GI.1 and GII.4, respectively. The potential for widespread vaccination against norovirus, particularly in high-burden populations such as young children and older adults, supports a compelling market opportunity due to the significant healthcare costs associated with norovirus-induced acute gastroenteritis. Furthermore, with HilleVax remaining well-capitalized and actively exploring development options for both HIL-214 and its newly licensed candidate HIL-216, there exists a strong foundation for future growth and value creation in the biopharmaceutical sector.

Bears say

HilleVax Inc. faces significant challenges following disappointing top-line data from the Phase 2b NEST-IN1 trial, which led to the discontinuation of development for its HIL-214 norovirus vaccine candidate intended for infants. The company's reported net loss of $40.7 million, or $0.83 per share for Q2 2024, raises concerns regarding its financial sustainability, further compounded by a substantial workforce reduction of approximately 40% aimed at cutting operating expenses. The risks associated with the future development of its vaccine candidates, including failure to secure necessary capital and achieve projected revenue estimates, contribute to a negative outlook on the stock's potential performance.

HilleVax Inc (HLVX) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HilleVax Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HilleVax Inc (HLVX) Forecast

Analysts have given HilleVax Inc (HLVX) a Buy based on their latest research and market trends.

According to 6 analysts, HilleVax Inc (HLVX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HilleVax Inc (HLVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.